Pacira BioSciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PCRX Nasdaq 2830 www.pacira.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pacira BioSciences, Inc.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 3rd, 2025 2:01 pm
Is the Options Market Predicting a Spike in Pacira BioSciences Stock? - Jun 18th, 2025 9:06 am
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 - Jun 18th, 2025 6:00 am
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee - Jun 11th, 2025 6:00 am
Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57% - May 22nd, 2025 7:01 am
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee - May 15th, 2025 6:00 am
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - May 14th, 2025 6:00 am
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates - May 9th, 2025 9:12 am
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... - May 9th, 2025 1:41 am
Pacira: Q1 Earnings Snapshot - May 8th, 2025 2:11 pm
Pacira BioSciences Reports First Quarter 2025 Financial Results - May 8th, 2025 2:00 pm
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis - May 6th, 2025 6:00 am
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis - May 2nd, 2025 6:00 am
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - Apr 29th, 2025 6:00 am
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee - Apr 28th, 2025 6:00 am
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee - Apr 22nd, 2025 2:01 pm
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders - Apr 21st, 2025 6:15 am
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - Apr 17th, 2025 3:00 pm
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? - Apr 15th, 2025 11:45 am
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Apr 10th, 2025 3:00 am